Adebrelimab maintenance for limited-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a maintenance drug called Adebrelimab after initial chemo with or without radiation for limited-stage small cell lung cancer. It aims to see if continuing the drug helps keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have limited-stage small cell lung cancer (cancer only in one lung and nearby nodes) and haven't been treated for it yet.
- Your tumors can be measured on scans (using standard criteria).
- Your overall health is good enough for daily activities (ECOG score 0 or 1).
- Your heart, liver, kidneys, and blood counts are within normal ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Adebrelimab as a maintenance therapy after you finish chemotherapy and radiation (given in smaller, more frequent doses) for limited-stage small cell lung cancer. The goal is to see if it helps keep the cancer from coming back.
This trial tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy and radiation for people with limited-stage small cell lung cancer. After the initial treatment, adebrelimab is continued alone to help prevent the cancer from coming back.
This study tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy and radiation treatment for patients with advanced non-small cell lung cancer that cannot be surgically removed. The goal is to improve how well treatment works and help patients live longer.
This study tests an immunotherapy (PD-L1 inhibitor) for people with limited-stage small cell lung cancer whose cancer stayed stable after chemo and radiation but still has MRD (small traces of cancer in the blood). The goal is to see if this treatment can help prevent the cancer from coming back.
This trial tests a combination of two drugs (adebrelimab and etoposide capsules) as maintenance therapy for people with extensive-stage small cell lung cancer who have not progressed after initial treatment. It may help extend the time before the cancer grows back.
This study tests a new maintenance therapy (adebrelimab plus apatinib) for people with extensive-stage small cell lung cancer who have already responded to initial chemotherapy and immunotherapy. The goal is to help keep the cancer from coming back longer.
Hear when a new Localized Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.